Q-omics provides the consensus-scored CSE1L-AS1 profile across patient tissues and cancer cell-line models. CSE1L-AS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CSE1L-AS1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CSE1L-AS1 RNA expression shows 7,585 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, BLCA, and LSCC as cancer lineages where CSE1L-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSE1L-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSE1L-AS1 survival associations across molecular data types. CSE1L-AS1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSE1L-AS1 RNA expression–survival associations across cancer types. High CSE1L-AS1 expression shows unfavorable associations in KICH, HNSC, KIRC and LIHC, but favorable associations in LUAD and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for CSE1L-AS1 RNA expression.
This table summarizes CSE1L-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSE1L-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSE1L-AS1 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, LUSC, LIHC and BRCA. The BLCA box plot shows higher CSE1L-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.235, t-test p < 0.001).
This table shows molecular features associated with CSE1L-AS1 in patient tissues and cancer cell lines. In patient samples, CSE1L-AS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
